Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CY-101, its lead asset, is a synthetic peptide engineered to selectively target tumor cells. CY-101 has a unique dual MoA applicable across solid tumors: (1) direct tumor-specific membrane lysis and in-situ vaccination, combined with (2) immune activation through inhibition of the β-catenin pathway. Building on strong FIH clinical data, Cytovation is advancing CY-101 to POC/pivotal clinical development with a focus on b-catenin-driven cancers.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Solheimsgaten 11, Bergen,5058,norway
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cytovation.com
- Keywords
- Biotech, Oncology, Immuno-oncology.
- HQ
- Bergen
Cytovation Questions
Cytovation's website is cytovation.com
Cytovation's LinkedIn profile is https://no.linkedin.com/company/cytovation-asa
Cytovation has
12 employees.
View email and phone details for 12
employees at Cytovation.
Cytovation's industry is
Biotechnology Research
Cytovation's top competitors are
Algipharma As,
Arctic Bioscience,
Thor Medical Asa,
Ultimovacs Asa,
Leti Pharma,
Bergenbio Asa,
Lytix Biopharma,
Nexkin Medical,
Vb Devices,
Nykode Therapeutics.
Cytovation's categories are Biotechnology Research
Cytovation's founding year is 2015
